Printed as of 12/14/2025

Disclosures

Personal Commercial (7)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Abbott, Bristol-Meyers-Squibb, Crisper,Cytokinetics,Editas Medicine, Intuitive Surgical, Johnson & Johnson, Merck, Moderna, Proctor & Gamble, C4 Theraputics	Stock	None (\$0)	General Cardiology Other
Amarin Reduce-IT trial - EPA Omega 3 randomized trial for triglycerides-finished > 12 months ago	Research/Research Grants	Modest (< \$5,000)	Prevention
Anthera - Cleveland Clinic trial - study site- finished >12 months ago	Research/Research Grants	Modest (< \$5,000)	General Cardiology
Novartis - Harvard Hospitals- Brigham, I think- finished > 12 months ago	Research/Research Grants	Modest (< \$5,000)	General Cardiology
Novartis ASTRONAUT multicenter trial finished >12 months ago 2013 Aliskiren	Research/Research Grants	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Pfizer finished >12 months ago	Research/Research Grants	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
ROCHE -Daletrapib trial finished >12 months ago	Research/Research Grants	Modest (< \$5,000)	General Cardiology Prevention

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (4)

Non-Commercial Enity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Geroge Washington University Hospital Pharmacy Department † GWUH Pharmacy department -2019 last event	Other - Speaker at symposium	Modest (< \$5,000)	Prevention
National Cancer Institute of Canada Clinical trials Group-NCIC	Research/Research Grants	Significant (>= \$5,000)	Prevention
NIH- WARCEF Warfarin Vs Aspirin † N/A	Research/Research Grants	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
NIH- Women's Health Initiative † NO	Research/Research Grants	Significant (>= \$5,000)	Prevention General Cardiology

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 8/31/2022

URL for full agreement: http://disclosures. acc. org/Public/Definition/Certified Education Attest at ion Agreement to the property of th

Confidentiality, Disclosure and Assignment Agreement | Signed on 8/31/2022

URL for full agreement: http://disclosures.acc.org/Public/Definition/Confidentiality Disclosure and Assignment Agreement Agreement Agreement and Assignment Agreement and Assignment Agreement Agre

Embargo | Signed on 8/31/2022

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 8/31/2022

ACC and **Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.